Valsartan is an angiotensin II receptor blocker indicated for hypertension and heart failure. We supply it to US manufacturers of tablets, capsules and fixed-dose combinations.
Data from PubChem (CID 60846) and FDA’s substance registry
CAS number
137862-53-4
Molecular formula
C24H29N5O3
Molecular weight
435.5g/mol
FDA UNII
IUPAC name
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
InChIKey
ACWBQPMHZXGDFX-QFIPXVFZSA-N
- Appearance
- White or almost white, hygroscopic powder.
- Solubility
- Practically insoluble in water, freely soluble in anhydrous ethanol and sparingly soluble in methylene chloride.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
The molecule in which NDMA was first found in 2018. Expect a full nitrosamine risk assessment with confirmatory test data, and an azido impurity statement.
On the US market
- Reference product
- DiovanNDA 020665
- Approved ANDAs
- 18 with a marketed product
- Approved forms and strengths
- Tablet 40 mg, 80 mg, 160 mg, 320 mg
- Oral solution 4 mg/mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com